查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924738

核医放射性药物市场（依产品类型、放射性核种类型、最终用户和应用划分）－2026-2032年全球预测

Radiopharmaceuticals in Nuclear Medicine Market by Product Type, Radionuclide, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年核医放射性药物市值为97.8亿美元，预计2026年将成长至106.9亿美元，年复合成长率为10.37%，到2032年将达到195.2亿美元。

关键市场统计数据
基准年 2025 97.8亿美元
预计年份：2026年 106.9亿美元
预测年份 2032 195.2亿美元
复合年增长率 (%) 10.37%

本文简要介绍了分子影像和标靶放射性核素治疗如何重新定义现代医学的临床路径和生态系统动态。

放射性药物已从专科中心使用的特定示踪剂转变为现代诊断和治疗流程中不可或缺的组成部分。本文将基础科学置于临床应用的背景下，重点阐述了正子断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT) 如何与标靶放射疗法（可将细胞毒性药物直接输送到病变组织）同步过程。分子影像与治疗的融合重塑了诊断流程，并使伴随诊断能够指导精准治疗，从而增强了放射性核素干预在肿瘤学、神经病学和心臟病学领域的作用。

概述重塑诊断和治疗放射性药物的生产、监管和临床应用的主要变革性转变

放射性药物领域正经历着一场由技术创新、监管成熟和临床范式转移所驱动的变革浪潮。放射化学和发生器技术的进步扩大了短寿命同位素的获取途径，并实现了分散式生产模式，加速了临床试验的招募和临床应用。同时，α发射体疗法的兴起带来了新的疗效和安全性特征，需要相应的全新临床管理策略、专门的通讯协定和个人化的报销机制。因此，放射性同位素的可用性如今已成为医疗机构工作流程和资本规划的核心营运限制因素。

深入分析 2025 年美国关税调整对放射性药物供应链、筹资策略和物流的影响。

2025年公布的关税调整给支持放射性药物研发和分销的国际供应链带来了实际压力。前驱化学品、特殊试剂和部分辅助设备的进口关税提高，增加了许多製造商的到岸成本，迫使采购团队重新评估筹资策略和库存政策。为此，生产计画负责人已加大力度，尽可能加快关键投入品的在地采购，投资于双重采购安排，并重新谈判供应商合约以降低成本波动。

全面的細項分析表明，产品类型、临床应用案例、放射性同位素、最终用户和分销模式各自构成不同的策略要务。

放射性药物市场的细分凸显了不同产品类型、临床应用、放射性同位素、终端用户和分销管道需要不同的策略应对措施。产品差异化涵盖了用于PET和SPECT成像的诊断剂以及依赖α和β发射体的治疗剂。诊断性PET产品主要基于氟-18和镓-68平台，而SPECT应用则继续依赖碘-123和Technetium-99m。治疗产品组合包括α发射体，例如锕-225和镭-223，以及β发射体，例如碘-131、镏-177和钇-90。这种多样性在从研发到商业化的每个阶段都带来了不同的监管、生产和物流要求。

从区域观点出发，探讨基础设施、临床应用和策略投资如何影响美洲、欧洲、中东和非洲以及亚太地区的市场准入决策。

区域趋势对放射性药物的研发、应用和基础设施投资具有决定性影响。在美洲，成熟的临床需求、先进的影像网路以及不断扩充的治疗产品线共同推动了商业模式、报销谈判和整合式医疗路径的创新。在此背景下，研究型医院、契约製造和诊断中心之间的合作正在加速从临床试验到常规临床应用的转化，同时法规结构也在不断发展以适应新的治疗方法。

来自主要企业和机构的真知灼见，重点介绍了推动竞争优势的策略投资、合作伙伴生态系统和製造能力。

主要企业和机构正透过投资同位素生产、放射化学平台和临床开发项目，重塑放射性药物产业的格局。领先的商业机构正在拓展其服务组合，提供涵盖生产、品质保证和分销的端到端解决方案，从而降低医院系统和研究网路的复杂性。同时，学术机构和专科医院正透过研究者主导的临床研究和早期临床试验，提供关键的临床检验，帮助降低新型治疗方法的风险。

为领导者提供具体策略建议，以加强供应韧性、加速临床检验并确保放射性药物的报销途径。

为了创造放射性药物的长期价值，产业领导者应优先投资于增强供应链韧性、提高监管准备度和累积临床证据。加强区域生产能力并采用分散式产生器模式可以降低跨境物流和关税波动带来的风险。在进行基础设施投资的同时，各机构应与学术机构和专科诊所建立正式的策略合作伙伴关係，以加速转化研究并产生真实世界证据，从而支持药品报销和扩大临床应用。

对依证调查方法进行清晰阐述，该方法结合了相关人员访谈、监管审查和技术整合，以确保研究结果的可靠性。

该报告的调查方法整合了一手和二手讯息，旨在为放射性药物行业提供严谨且基于证据的观点。一手资讯包括对放射化学家、临床研究人员、医院药房主任和供应链高管的结构化访谈，以及与监管和报销专家的咨询。与这些相关人员的讨论提供了有关生产限制、临床应用驱动因素和最佳营运实践的定性背景资讯。

简明扼要的结论总结了技术进步、营运复杂性和相关人员合作将如何决定放射性药物领域未来的成功。

结论部分概述了科学创新、供应链趋势以及不断变化的监管和报销环境如何共同塑造放射性药物领域的机会和风险。诊断和治疗方法正在精准医疗应用中融合，这需要对生产、临床检验和分销基础设施进行协调投资。能够将生产可靠性与临床证据产生和与支付方的合作相结合的企业，将获得策略差异化优势。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 核医放射性药物市场（依产品类型划分）

  • 诊断用放射性药物
    • PET
      • 氟-18放射性药物
      • 镓-68放射性药物
    • SPECT
      • 碘-123放射性药物
      • Technetium-99m放射性药物
  • 治疗性放射性药物
    • 阿尔法发射体
      • 锕-225
      • 镭-223
    • β射线放射体
      • 碘-131
      • 镏-177
      • 钇-90

9. 依放射性核种类型分類的核医放射性药物市场

  • 氟18
  • 碘-131
  • 镏-177
  • Technetium-99m
  • 钇-90

第十章 核医放射性药物市场（依最终用户划分）

  • 学术研究机构
  • 医院和诊所
    • 私人诊所
    • 公立医院
  • 医学影像检查中心
    • 影像检查中心
    • 专业治疗中心

第十一章 核医放射性药物市场（依应用领域划分）

  • 脑部影像
    • PET脑部药物
    • SPECT脑部药物
  • 心臟病学
    • 灌注影像
    • 可行性成像
  • 肿瘤学
    • PET影像
      • 氟-18放射性药物
      • Technetium-99m放射性药物
    • 治疗
      • α粒子疗法
      • β射线疗法

第十二章 核医放射性药物市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 核医放射性药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国核医放射性药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国核医放射性药物市场

第十六章：中国核医放射性药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bracco Imaging SpA
  • BWXT Medical Ltd.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Pty Ltd
  • Curium Pharma SAS
  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Eli Lilly and Company
  • GE HealthCare, Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • PharmaLogic Holdings Corp.
  • RayzeBio, Inc.
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C469

The Radiopharmaceuticals in Nuclear Medicine Market was valued at USD 9.78 billion in 2025 and is projected to grow to USD 10.69 billion in 2026, with a CAGR of 10.37%, reaching USD 19.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.78 billion
Estimated Year [2026] USD 10.69 billion
Forecast Year [2032] USD 19.52 billion
CAGR (%) 10.37%

A concise introduction to how molecular imaging and targeted radionuclide therapies are redefining clinical pathways and ecosystem dynamics in modern healthcare

Radiopharmaceuticals have transitioned from niche tracers used in specialized centers to integral components of contemporary diagnostic and therapeutic care pathways. This introduction frames the foundational science through the lens of clinical adoption, emphasizing how positron emission tomography and single photon emission computed tomography have matured alongside targeted radiotherapeutics that deliver cytotoxic payloads directly to pathologic tissues. The convergence of molecular imaging and molecular therapy has reshaped diagnostic algorithms and enabled companion diagnostics that guide precision treatments, thereby elevating the role of radionuclide-based interventions across oncology, neurology, and cardiology.

Beyond clinical utility, the ecosystem that supports radiopharmaceuticals encompasses isotope production, radiochemistry, regulatory oversight, and complex logistics that preserve radionuclide integrity. As manufacturing technologies evolve and therapeutic alpha and beta emitters advance into later-stage clinical development, stakeholders must adapt to shorter supply chains, higher regulatory scrutiny, and novel reimbursement conversations. This introduction sets the stage for deeper analysis by outlining the scientific trajectory and commercial context that propel the radiopharmaceuticals landscape forward.

An overview of the major transformative shifts reshaping production, regulation, and clinical adoption across diagnostic and therapeutic radiopharmaceuticals

The radiopharmaceuticals sector is undergoing transformative shifts driven by technological innovation, regulatory maturation, and changing clinical paradigms. Advances in radiochemistry and generator technologies have expanded access to short-lived isotopes and enabled decentralized production models, which in turn accelerate trial enrollment and clinical adoption. Meanwhile, the rise of alpha-emitter therapeutics has introduced new efficacy and safety profiles that demand fresh clinical management strategies, specialized handling protocols, and tailored reimbursement frameworks. As a result, institutional workflows and capital planning now integrate isotope availability as a core operational constraint.

Parallel to technological shifts, regulatory pathways are adapting to accommodate companion diagnostics and novel therapeutic constructs while emphasizing patient safety and manufacturing traceability. Payer engagement is similarly evolving, with value-based discussions increasingly focused on downstream clinical and economic outcomes rather than acquisition cost alone. These converging forces are driving collaborations across academic centers, contract manufacturers, and commercial sponsors, thereby reshaping competitive dynamics and creating opportunities for integrated service offerings that span production, delivery, and clinical utilization.

A detailed analysis of how the 2025 United States tariff adjustments reshaped supply chains, procurement strategies, and logistics for radiopharmaceuticals

Tariff changes announced in 2025 introduced tangible pressures across international supply chains that support radiopharmaceutical development and distribution. Increased import duties on precursor chemicals, specialized reagents, and some ancillary equipment raised landed costs for many manufacturers, compelling procurement teams to revisit sourcing strategies and inventory policies. In turn, production planners accelerated efforts to localize critical inputs where feasible, invest in dual-sourcing arrangements, and renegotiate supplier contracts to mitigate cost volatility.

Logistics and cold-chain providers faced higher cross-border handling fees that complicated time-sensitive deliveries of short-lived isotopes, prompting a renewed emphasis on regional distribution networks and on-site generator solutions. Clinical trial sponsors and hospital networks felt downstream effects as operational budgets absorbed incremental transport and material expenses, which necessitated strategic reprioritization of pipeline activities and capital projects. In response, industry participants pursued policy engagement with regulators and trade authorities to secure exemptions for clinical and research materials, while concurrently exploring manufacturing innovations and public-private partnerships to sustain access and control costs.

Comprehensive segmentation insights revealing how product types, clinical use cases, radionuclides, end users, and distribution models create distinct strategic imperatives

Segmenting the radiopharmaceuticals landscape clarifies how product types, clinical applications, radionuclides, end users, and distribution channels each demand distinct strategic responses. Product differentiation spans diagnostic agents used in PET and SPECT imaging and therapeutic agents that rely on alpha and beta emitters; diagnostic PET offerings emphasize fluorine-18 and gallium-68 platforms, while SPECT applications remain anchored to iodine-123 and technetium-99m chemistry, and therapeutic portfolios include actinium-225 and radium-223 among alpha options and iodine-131, lutetium-177, and yttrium-90 among beta emitters. This diversity drives separate regulatory, manufacturing, and logistical requirements across development and commercialization pathways.

Clinical applications further segment demand by brain imaging, cardiology, and oncology, with brain agents differentiated into PET and SPECT modalities, cardiology encompassing perfusion and viability imaging with specific tracer classes, and oncology spanning both diagnostic PET imaging with fluorine-18 and technetium-99m tracers and targeted therapy using alpha and beta emitter constructs. Radionuclide-focused segmentation highlights unique handling and production needs for fluorine-18, iodine-131, lutetium-177, technetium-99m, and yttrium-90. End-user segmentation identifies academic and research institutions, hospitals and clinics including private and public facilities, and imaging centers that range from diagnostic-only operations to specialty therapy centers. Distribution channels bifurcate into direct sales and indirect sales through distributors and wholesalers, with wholesaler networks further differentiated across national and regional players. Together, these segmentation lenses inform tailored product design, go-to-market strategies, and investment in manufacturing and distribution infrastructure.

A regional perspective on infrastructure, clinical adoption, and strategic investment across the Americas, EMEA, and Asia-Pacific that shapes market entry decisions

Regional dynamics exert a decisive influence on radiopharmaceutical development, adoption, and infrastructure investment. The Americas combine mature clinical demand, advanced imaging networks, and a growing therapeutic pipeline, which encourages innovation in commercial models, reimbursement negotiation, and integrated care pathways. In this environment, partnerships between research hospitals, contract manufacturers, and diagnostic centers accelerate translation from clinical trials to routine clinical use while regulatory frameworks continue to evolve to accommodate new modalities.

Europe, the Middle East, and Africa present a heterogeneous mix of capability and demand: some markets exhibit strong regulatory harmonization and established nuclear medicine services, while others focus on building capacity through regional manufacturing hubs and training initiatives. In these regions, cross-border collaborations and centralized isotope producers play a central role in widening access. The Asia-Pacific region demonstrates rapid capacity expansion driven by rising healthcare investment, increasing oncology burden, and strategic public-private initiatives to localize isotope production and radiopharmacy expertise. Each region's trajectory informs decisions on where to prioritize manufacturing investments, clinical partnerships, and market-entry sequencing.

Key company and institutional insights highlighting strategic investments, partner ecosystems, and manufacturing capabilities that drive competitive advantage

Leading companies and institutional players shape the radiopharmaceuticals landscape through investments in isotope production, radiochemistry platforms, and clinical development programs. Key commercial entities have expanded their service portfolios to offer end-to-end solutions that combine manufacturing, quality assurance, and distribution, thereby reducing complexity for hospital systems and research networks. At the same time, academic centers and specialized hospitals contribute critical clinical validation through investigator-initiated studies and early-phase trials that de-risk novel therapeutic constructs.

Strategic alliances between technology providers, contract manufacturing organizations, and clinical sponsors have become instrumental in scaling production of both diagnostic tracers and therapeutic agents. These partnerships frequently target capacity expansion, regulatory filings, and optimized logistics for short-lived isotopes. Investors and corporate development teams have also prioritized capabilities that enable rapid translation from radiochemistry advances to GMP-compliant manufacturing, acknowledging that differentiated production and distribution capabilities will determine competitive positioning in both diagnostic and therapeutic market segments.

Actionable strategic recommendations for leaders to strengthen supply resilience, accelerate clinical validation, and secure reimbursement pathways for radiopharmaceuticals

Industry leaders should prioritize investments that enhance supply resilience, regulatory readiness, and clinical evidence generation to capture long-term value in radiopharmaceuticals. Strengthening regional production capacity and adopting decentralized generator models can mitigate the risks associated with cross-border logistics and tariff volatility. Alongside infrastructure investment, organizations should formalize strategic partnerships with academic centers and specialty clinics to accelerate translational research and generate real-world evidence that supports reimbursement and broader clinical adoption.

Operational excellence in radiopharmacy processes, cold-chain logistics, and quality systems will differentiate providers as therapeutic radiopharmaceuticals enter later-stage development. Companies should also engage proactively with regulatory bodies and payers to shape pragmatic pathways for approval and reimbursement that reflect therapeutic value over time. Finally, building internal commercial capabilities that educate clinicians and streamline patient access will be essential to converting clinical potential into consistent utilization across diagnostic and therapeutic indications.

A clear explanation of the evidence-based research methodology combining stakeholder interviews, regulatory review, and technical synthesis to ensure robust insights

The research methodology for this report synthesizes primary and secondary inputs to deliver a rigorous, evidence-based perspective on the radiopharmaceuticals landscape. Primary inputs include structured interviews with radiochemists, clinical investigators, hospital pharmacy directors, and supply chain executives, as well as consultations with regulatory specialists and reimbursement experts. These stakeholder discussions provide qualitative context on manufacturing constraints, clinical adoption drivers, and operational best practices.

Secondary research integrates peer-reviewed literature, regulatory guidance documents, technical standards for radiopharmacy, and company disclosures to validate findings and identify industry trends. Data were triangulated across sources to ensure consistency and to highlight areas of divergence that warrant further investigation. The methodology emphasizes transparency in assumptions, a focus on operational and clinical drivers rather than purely commercial metrics, and iterative validation with subject-matter experts to refine conclusions and recommendations.

A concise conclusion synthesizing how technological progress, operational complexity, and stakeholder alignment determine future success in radiopharmaceuticals

The conclusion synthesizes how scientific innovation, supply chain dynamics, and evolving regulatory and reimbursement environments collectively shape opportunities and risks in radiopharmaceuticals. Diagnostic and therapeutic modalities are converging around precision applications that demand coordinated investment in production, clinical validation, and distribution infrastructure. Strategic differentiation will accrue to organizations that can marry manufacturing reliability with clinical evidence generation and payer engagement.

Looking forward, the sector will continue to balance rapid technological progress with operational complexity, requiring adaptive strategies that prioritize patient access and safety. Stakeholders who align commercial plans with investments in decentralized production, quality systems, and strategic partnerships will be best positioned to translate advances in radiochemistry and targeted therapies into sustainable clinical and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceuticals in Nuclear Medicine Market, by Product Type

  • 8.1. Diagnostic Radiopharmaceuticals
    • 8.1.1. PET
      • 8.1.1.1. Fluorine-18 Radiopharmaceuticals
      • 8.1.1.2. Gallium-68 Radiopharmaceuticals
    • 8.1.2. SPECT
      • 8.1.2.1. Iodine-123 Radiopharmaceuticals
      • 8.1.2.2. Technetium-99m Radiopharmaceuticals
  • 8.2. Therapeutic Radiopharmaceuticals
    • 8.2.1. Alpha Emitter
      • 8.2.1.1. Actinium-225
      • 8.2.1.2. Radium-223
    • 8.2.2. Beta Emitter
      • 8.2.2.1. Iodine-131
      • 8.2.2.2. Lutetium-177
      • 8.2.2.3. Yttrium-90

9. Radiopharmaceuticals in Nuclear Medicine Market, by Radionuclide

  • 9.1. Fluorine-18
  • 9.2. Iodine-131
  • 9.3. Lutetium-177
  • 9.4. Technetium-99m
  • 9.5. Yttrium-90

10. Radiopharmaceuticals in Nuclear Medicine Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospitals & Clinics
    • 10.2.1. Private Clinics
    • 10.2.2. Public Hospitals
  • 10.3. Imaging Centers
    • 10.3.1. Diagnostic Imaging Centers
    • 10.3.2. Specialty Therapy Centers

11. Radiopharmaceuticals in Nuclear Medicine Market, by Application

  • 11.1. Brain Imaging
    • 11.1.1. PET Brain Agents
    • 11.1.2. SPECT Brain Agents
  • 11.2. Cardiology
    • 11.2.1. Perfusion Imaging
    • 11.2.2. Viability Imaging
  • 11.3. Oncology
    • 11.3.1. PET Imaging
      • 11.3.1.1. Fluorine-18 Radiopharmaceuticals
      • 11.3.1.2. Technetium-99m Radiopharmaceuticals
    • 11.3.2. Therapy
      • 11.3.2.1. Alpha Emitter Therapy
      • 11.3.2.2. Beta Emitter Therapy

12. Radiopharmaceuticals in Nuclear Medicine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Radiopharmaceuticals in Nuclear Medicine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Radiopharmaceuticals in Nuclear Medicine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Radiopharmaceuticals in Nuclear Medicine Market

16. China Radiopharmaceuticals in Nuclear Medicine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Actinium Pharmaceuticals, Inc.
  • 17.6. AstraZeneca plc
  • 17.7. Bayer AG
  • 17.8. Bracco Imaging S.p.A.
  • 17.9. BWXT Medical Ltd.
  • 17.10. Cardinal Health, Inc.
  • 17.11. Clarity Pharmaceuticals Pty Ltd
  • 17.12. Curium Pharma SAS
  • 17.13. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 17.14. Eli Lilly and Company
  • 17.15. GE HealthCare, Inc.
  • 17.16. ITM Isotope Technologies Munich SE
  • 17.17. Jubilant Pharmova Limited
  • 17.18. Lantheus Holdings, Inc.
  • 17.19. NorthStar Medical Radioisotopes LLC
  • 17.20. Novartis AG
  • 17.21. PharmaLogic Holdings Corp.
  • 17.22. RayzeBio, Inc.
  • 17.23. Siemens Healthineers AG
  • 17.24. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GALLIUM-68 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GALLIUM-68 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GALLIUM-68 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-123 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-123 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-123 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIUM-223, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIUM-223, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECIALTY THERAPY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECIALTY THERAPY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECIALTY THERAPY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET BRAIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET BRAIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET BRAIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT BRAIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT BRAIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT BRAIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PERFUSION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PERFUSION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PERFUSION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY VIABILITY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY VIABILITY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY VIABILITY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC RADIOPHARMACEUTICALS IN NUCLEAR MEDICIN